| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/05/2006 | WO2006000567A2 Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function |
| 01/05/2006 | WO2006000564A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
| 01/05/2006 | WO2006000555A2 Novel unsaturated tetracyclic tetrahydrofuran derivatives |
| 01/05/2006 | WO2006000421A2 Ige antibody repressing agent comprising alpha cyclodextrin |
| 01/05/2006 | WO2006000397A1 Novel use of peptide compounds for treating essential tremor and other tremor syndromes |
| 01/05/2006 | WO2006000387A1 Diabetes-treating method |
| 01/05/2006 | WO2006000371A2 Pyrimidine derivatives as 11beta-hsd1 inhibitors |
| 01/05/2006 | WO2006000324A2 New mao-b inhibitors |
| 01/05/2006 | WO2006000306A1 Use of meloxicam in veterinary medicine for the treatment of inflammatory painful diseases |
| 01/05/2006 | WO2006000293A1 Ortho-substituted (3-hydroxyphenyl)-acetic acid benzylidene hydrazides |
| 01/05/2006 | WO2006000233A1 Tobacco alkaloid containing chewing gum |
| 01/05/2006 | WO2006000232A1 Tobacco alkaloid releasing chewing gum |
| 01/05/2006 | WO2006000228A2 Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention |
| 01/05/2006 | WO2006000224A2 Compositions comprising strontium and vitamin d and uses thereof |
| 01/05/2006 | WO2006000222A2 The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia |
| 01/05/2006 | WO2006000158A1 The use of laetispicine for manufacture of pharmaceutical composition |
| 01/05/2006 | WO2006000137A1 Oral disintegrable tablet of notogingseng total sapoin and the preparation process thereof |
| 01/05/2006 | WO2005112990A3 Treatment of diseases associated with the use of antibiotics |
| 01/05/2006 | WO2005112974A3 Peptide-modified polyurethane compositions and associated methods |
| 01/05/2006 | WO2005110386A3 Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers |
| 01/05/2006 | WO2005107773A3 Solid dosage form of wetted heparin |
| 01/05/2006 | WO2005102297A3 Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma |
| 01/05/2006 | WO2005100352A8 Selected cgrp-antagonists, their preparation processes and their use as medicaments |
| 01/05/2006 | WO2005099709A3 Bicyclic heterocycles useful as serine protease inhibitors |
| 01/05/2006 | WO2005097796A3 Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one |
| 01/05/2006 | WO2005097079A3 Controlled release dosage for gaba receptor agonist |
| 01/05/2006 | WO2005097076A3 Low dose pharmaceutical products |
| 01/05/2006 | WO2005095450A3 Therapeutic use of a growth factor, nsg33 |
| 01/05/2006 | WO2005095364A8 Phenoxyacetic acid derivative and medicine containing the same |
| 01/05/2006 | WO2005094333A8 Multi-vitamin and mineral nutritional supplements |
| 01/05/2006 | WO2005094329A8 Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor |
| 01/05/2006 | WO2005092335B1 TETRAHYDRO-β-CARBOLINE COMPOUNDS AND USE THEREOF |
| 01/05/2006 | WO2005089772A3 Prevention of loss of tight cell junctions using carbohydrate-containing compositions |
| 01/05/2006 | WO2005089448A3 Administration of cisplatin by inhalation |
| 01/05/2006 | WO2005085259A3 Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines |
| 01/05/2006 | WO2005082371A3 Oral dieting composition comprising conjugated linoleic acid and caffeine |
| 01/05/2006 | WO2005079763A3 Compression-coated tablets and manufacture thereof |
| 01/05/2006 | WO2005077370A8 Aqueous solution preparation containing camptothecins |
| 01/05/2006 | WO2005077126A3 Use of PPARgamma specific inhibitors as anti-cancer therapeutics |
| 01/05/2006 | WO2005072745A3 Aqueous solutions comprising prednisolone and a cyclodextrin derivative |
| 01/05/2006 | WO2005070043A3 Methods for treating non-melanoma cancers with paba |
| 01/05/2006 | WO2005070003A3 Abuse potential reduction in abusable substance dosage form |
| 01/05/2006 | WO2005061446A3 Processes for the preparation of aminoalkyl phenylcarbamates |
| 01/05/2006 | WO2005060961A3 Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd) |
| 01/05/2006 | WO2005060540A3 Norethindrone sustained release transdermal formulation |
| 01/05/2006 | WO2005059107A3 Chemokine receptor binding compounds |
| 01/05/2006 | WO2005058002A3 High efficiency fullerene-based radical scavengers |
| 01/05/2006 | WO2005055929A3 Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
| 01/05/2006 | WO2005053709A3 Pharmaceutical uses of bisphosphonates |
| 01/05/2006 | WO2005009377A3 Novel oral bioavailable prodrugs |
| 01/05/2006 | WO2005009345A3 2-desmethyl ansamycin compounds |
| 01/05/2006 | WO2005000357A3 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/05/2006 | WO2004093813A3 Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
| 01/05/2006 | WO2004091504A3 Substituted quinobenzoxazine analogs |
| 01/05/2006 | WO2004080976A8 Phthalazinone derivatives |
| 01/05/2006 | WO2004071453A3 Compositions and methods for treatment of pouchitis |
| 01/05/2006 | WO2004071441A3 Compositions and methods to modulate immune and inflammatory responses |
| 01/05/2006 | WO2004040997A3 Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine |
| 01/05/2006 | WO2004017908A3 Calcium receptor modulating compound and use thereof |
| 01/05/2006 | WO2004008946A3 Methods of diagnosing and treating pre-eclampsia or clamp |
| 01/05/2006 | WO2003102153A3 Cell migration inhibiting compositions and methods and compositions for treating cancer |
| 01/05/2006 | WO2003087338A3 Her-2 receptor tyrosine kinase molecules and uses thereof |
| 01/05/2006 | WO2003031406A3 Kinase inhibitor scaffolds and methods for their preparation |
| 01/05/2006 | WO2003016493A3 Transporters and ion channels |
| 01/05/2006 | US20060004314 Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
| 01/05/2006 | US20060004230 Process for the preparation of terbinafine and salts thereof |
| 01/05/2006 | US20060004207 Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods |
| 01/05/2006 | US20060004204 Process for preparation of montelukast and its salts |
| 01/05/2006 | US20060004203 Modified pictet-spengler reaction and products prepared therefrom |
| 01/05/2006 | US20060004200 Processes to produce intermediates for rosuvastatin |
| 01/05/2006 | US20060004190 Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof |
| 01/05/2006 | US20060004109 Cyclopropanating 1-(2-allyloxyethyl)-4-benzyloxybenzene by the Simmon-Smith reaction with Furukawa modification to obtain the enantiomer 1-benzyloxy-4-(2-cyclopropyl methoxyethyl)benzene of high purity; avoiding the use of highly lacrymatric and unstable cyclopropylmethyl halide |
| 01/05/2006 | US20060004108 N-[3,5-bis(trifluoromethyl)phenyl]-1,8,8-trimethyl-2,4-dioxobicyclo[3.2.1]octane-3-carboxamide; treating convulsions, epilepsy, episodic ataxia, myokymia, neonatal convulsions, cerebral ischemia, cerebral palsy, stroke, traumatic brain injury, traumatic spinal cord injury |
| 01/05/2006 | US20060004107 Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same |
| 01/05/2006 | US20060004106 For urogenital disorders; improved side effect reduction, bioavailability, pharmacokinetics and half-life; N,N-diisopropyl-3-(2-methoxy-5-trifluoromethylphenyl)-3-phenylpropanamine |
| 01/05/2006 | US20060004105 Pharmaceutical composition for treating stress incontinence and/or mixed incontinence |
| 01/05/2006 | US20060004104 Use of 5-alkyl substituted 2-arylaminophenylacetic acid derivatives as selective cyclooxygenase-2 inhibitors in the treatment of cancer pain, especially bone cancer pain; for example, 5-methyl-2-(2'-chloro-6'-fluoroanilino)-phenylacetic acid |
| 01/05/2006 | US20060004103 Method for producing lysine derivative |
| 01/05/2006 | US20060004102 Crystal structure; comminution in solvent; crystallization; antidiabetic agents |
| 01/05/2006 | US20060004101 Inhibitor for liver cancer onset and progress |
| 01/05/2006 | US20060004100 Method of improving animal tissue quality by supplementing the animal diet with oleic acid and selected tocols |
| 01/05/2006 | US20060004099 Glycogen or polysaccharide storage disease treatment method |
| 01/05/2006 | US20060004098 N-Methyl-2,2,3,3-tetramethylcyclopropanecarboxamide; neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration; analgesic; side effect reduction |
| 01/05/2006 | US20060004097 Anti-retroviral moronic acid derivatives |
| 01/05/2006 | US20060004096 Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases |
| 01/05/2006 | US20060004095 Use of acetyl L-carnitine for the preparation of a medicine for the treatment of neuropathic pain in diabetic patients |
| 01/05/2006 | US20060004094 Composition and method for treating hemorrhoids and/or anorectal disorders |
| 01/05/2006 | US20060004093 obesity; antidiabetic agents; Alzheimer's disease; Huntington's disease;schizophrenia; anticancer agents; psoriasis; antiepileptic agents; strokes |
| 01/05/2006 | US20060004091 Alpha-phenoxy- or phenylthio-alkanoic acid derivatives in which the phenyl ring is substituted with an acetylene group, e.g., 2-methyl-2-{2-methyl-4-[4-(4-trifluoromethyl-phenyl)-but-3-ynylsulfanyl]-phenoxy}-propionic acid; PPAR delta and/or PPAR alpha agonists used to treat diabetes |
| 01/05/2006 | US20060004090 Forskolin compositions and methods for administration |
| 01/05/2006 | US20060004089 Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophthalmic topical use capable of improving the level of l-ascorbic acid in the eye |
| 01/05/2006 | US20060004088 Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same |
| 01/05/2006 | US20060004087 Tetracyclic compounds as estrogen ligands |
| 01/05/2006 | US20060004086 Method of reducing Abeta42 and treating diseases |
| 01/05/2006 | US20060004085 Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
| 01/05/2006 | US20060004084 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 01/05/2006 | US20060004083 Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists |
| 01/05/2006 | US20060004082 6H-thieno'2, 3-b!pyrrole derivatives as antagonists of gonadotropin releasing hormone (gnrh) |
| 01/05/2006 | US20060004081 Cytotoxic compounds and conjugates |
| 01/05/2006 | US20060004080 Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto |